Biological therapies for premature ovarian insufficiency: what is the evidence?
Frontiers in Reproductive Health · 07.09.2023 · 5
DOI: 10.3389/frph.2023.1194575 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Reproductive Health, online erschienen am 07.09.2023. Verfasst von Melpomeni Moustaki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes Center, Hellenic Red Cross Hospital, Athens, Greece. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Premature Ovarian Insufficiency (POI) is a multi-factorial disorder that affects women of reproductive age. The condition is characterized by the loss of ovarian function before the age of 40 years and several factors have been identified to be implicated in its pathogenesis. Remarkably though, at least 50% of women have remaining follicles in their ovaries after the development of ovarian insufficiency. Population data show that approximately up to 3.7% of women worldwide suffer from POI and subsequent infertility. Currently, the treatment of POI-related infertility involves oocyte donation. However, many women with POI desire to conceive with their own ova. Therefore, experimental biological therapies, such as Platelet-Rich Plasma (PRP), Exosomes (exos) therapy, In vitro Activation (IVA), Stem Cell therapy, MicroRNAs and Mitochondrial Targeting Therapies are experimental treatment strategies that focus on activating oogenesis and folliculogenesis, by upregulating natural biochemical pathways (neo-folliculogenesis) and improving ovarian microenvironment. This mini-review aims at identifying the main advantages of these approaches and exploring whether they can underpin existing assisted reproductive technologies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Diabetes Center, Hellenic Red Cross Hospital, Athens, Greece.
- Serum IVF Fertility Center, Athens, Greece.
- Department of Obstetrics and Gynecology, University of Crete Medical School, Heraklion, Greece.
- 3rd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Zitieren
APA
Moustaki, M., Kontogeorgi, A., Tsangkalova, G., Tzoupis, H., Makrigiannakis, A., Vryonidou, A., & Kalantaridou, S. N. (2023). Biological therapies for premature ovarian insufficiency: what is the evidence?. Frontiers in Reproductive Health, 5. https://doi.org/10.3389/frph.2023.1194575
Vancouver
Moustaki M, Kontogeorgi A, Tsangkalova G, Tzoupis H, Makrigiannakis A, Vryonidou A, et al. Biological therapies for premature ovarian insufficiency: what is the evidence?. Frontiers in Reproductive Health. 2023;5. doi:10.3389/frph.2023.1194575
BibTeX
@article{Moustaki2023,
author = {Moustaki, Melpomeni and Kontogeorgi, Adamantia and Tsangkalova, Gkalia and Tzoupis, Haralampos and Makrigiannakis, Antonis and Vryonidou, Andromachi and Kalantaridou, Sophia N},
title = {Biological therapies for premature ovarian insufficiency: what is the evidence?},
journal = {Frontiers in Reproductive Health},
year = {2023},
volume = {5},
doi = {10.3389/frph.2023.1194575}
}
EUVIMED